CMAB Biopharma, a Chinese full-service contract development and manufacturing organization (CDMO) providing process development and manufacturing services for biologic products, raised $34 million financing.
The funding proceeds will be used to upgrade CMAB’s 2,000L GMP facilities, expand manufacturing capacity and will also enable the company to provide 50L/200L/500L/1,000L/2,000L bioreactor scale GMP manufacturing services.
Located 80km west of Shanghai, CMAB’s new manufacturing facility, will provide services for the development of manufacturing process, analytical method, formulation, and the manufacture of biologic drug substances and drug products. The initial facility will be able to generate pre-clinical and early-stage clinical (Phase I/II) products, using manufacturing that follows global GMP standards, including those of the China Food & Drug Administration, US Food & Drug Administration (21 CFR), European Medicines Agency (Eudralex), WHO, and harmonized PIC/S and ICH standards.
According to CMAB’s current press-release, the company has already entered into collaboration agreements with several leading biopharma companies.